Ujiri Pharmaceuticals Private Limited
Founded in 2017 and headquartered in Haryana, India.
2017 | Faridabad, Haryana (India) | Active
Ujiri Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 812.06%
- Profit Growth -69.59%
- Ebitda 50.85%
- Net Worth 3.73%
- Total Assets 59.81%
About Ujiri Pharmaceuticals
Ujiri Pharmaceuticals Private Limited (UPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 September 2017 (Seven years and five months 17 days old ). Its registered office is in Faridabad, Haryana, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pavneesh Kumar and Gaurav Tanwar serve as directors at the Company.
Company Details
- Location
Faridabad, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909HR2017PTC070717
- Company No.
070717
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Sep 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Trading
Other Industry
Who are the key members and board of directors at Ujiri Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pavneesh Kumar  | Director | 11-Sep-2017 | Current |
| Gaurav Tanwar | Director | 11-Sep-2017 | Current |
Financial Performance of Ujiri Pharmaceuticals.
Ujiri Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 812.06% increase. The company also saw a substantial fall in profitability, with a 69.59% decrease in profit. The company's net worth moved up by a moderate rise of 3.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ujiri Pharmaceuticals?
Unlock access to Ujiri Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ujiri Pharmaceuticals?
Unlock and access historical data on people associated with Ujiri Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ujiri Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ujiri Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.